Trial Profile
A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Loncastuximab tesirine (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors ADC Therapeutics
- 23 Aug 2019 Status changed to discontinued.
- 16 Oct 2018 Status changed from active, no longer recruiting to completed.
- 28 Jun 2018 Status changed from recruiting to active, no longer recruiting.